NGL Fine-ChemNSE:NGLFINE -3.37%78 Pretax Margin % is 11.94% as of Mar. 2026, which is 26% below its 10-year median of 16.18. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,812.79 (Fairly Valued). The stock has 8 warning signs investors should review. Among 954 Drug Manufacturers companies, NGL Fine-Chem ranks better than 64.05% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. NGL Fine-Chem's Pre-Tax Income for the
three
months ended in Mar. 2026 was ₹178 Mil. NGL Fine-Chem's Revenue for the
three
months ended in Mar. 2026 was ₹1,492 Mil. Therefore, NGL Fine-Chem's pretax margin for the quarter that ended in Mar. 2026 was 11.94%.
The historical rank and industry rank for NGL Fine-Chem's Pretax Margin % or its related term are showing as below:
NSE:NGLFINE'
s Pretax Margin % Range Over the Past 10 Years
Min: 7.53 Med: 16.18 Max: 30.43
Current: 12.63
NSE:NGLFINE's Pretax Margin % is ranked better than 64.05% of 954
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs NSE:NGLFINE: 12.63
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
NGL Fine-Chem Pretax Margin % Related Terms
NGL Fine-Chem Pretax Margin % Historical Data
* Premium members only.
The historical data trend for NGL Fine-Chem's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NGLFINE vs LLY, JNJ, ABBV: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, NGL Fine-Chem's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NGL Fine-Chem Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where NGL Fine-Chem's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGL Fine-Chem (NSE:NGLFINE) has a Pretax Margin % of 11.94% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on NGL Fine-Chem and its competitors. This is 26% below median its historical median of 16.18. Over the past decade, NGL Fine-Chem's Pretax Margin % has ranged from 7.53 to 30.43. According to the industry distribution chart, NGL Fine-Chem ranks #343 out of 954 companies in the Drug Manufacturers industry, placing it in the top 36%.
Is NGL Fine-Chem's Pretax Margin % too high?
NGL Fine-Chem's current Pretax Margin % of 11.94% is 26% below median its 10-year median of 16.18. Over the past 10 years, this metric has ranged from a low of 7.53 to a high of 30.43. The Drug Manufacturers industry median Pretax Margin % is 7.30. NGL Fine-Chem's value of 11.94% is 63.7% above this industry median. Based on the distribution chart, NGL Fine-Chem ranks #343 out of 954 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's Pretax Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, NGL Fine-Chem ranks #343 out of 954 companies for Pretax Margin %. This puts NGL Fine-Chem in the upper half of its industry. The industry median Pretax Margin % is 7.30. NGL Fine-Chem's value of 11.94% is 63.7% above this benchmark. Historically, NGL Fine-Chem's own Pretax Margin % has ranged from 7.53 to 30.43 over the past decade. While the company's 10-year median is 16.18 vs. the industry median of 7.30, NGL Fine-Chem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current Pretax Margin % of 11.94% is 63.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on NGL Fine-Chem and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current Pretax Margin % is 11.94%, which is 26% below median its own 10-year median of 16.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,812.79, compared to a current price of ₹3,002.70 — trading 6.8% above its estimated fair value. The current Pretax Margin % is 11.94%, which is 26% below median its 10-year median of 16.18 and 63.7% above the Drug Manufacturers industry median of 7.30. NGL Fine-Chem's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current Pretax Margin % is 11.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?
Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued.
The current stock price of ₹3,002.70 is trading 6.8% above its estimated GF Value™ of ₹2,812.79.
GuruFocus considers NGL Fine-Chem to be Fairly Valued.
Key valuation signals for NSE:NGLFINE:
Pretax Margin %: 11.94% (26% below median its 10-year median of 16.18)
GF Value™: ₹2,812.79 vs. price of ₹3,002.70 (6.8% above fair value)
Industry Position: 63.7% above the Drug Manufacturers median (#343 of 954)
No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score
Get the complete analysis for NSE:NGLFINE
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NGLFINE has been successfully added to your 
